

Ref. No. JPL/CS/1473/2017

Date :5th December, 2017.

To
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Sub.:Outcome of Board Meeting held on 5th December, 2017 – Results for the Quarter ended on 30th September, 2017.

Reg.: Regulation 33 and 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Dear Sir,

Kindly note that the Audit Committee have reviewed and the Board of Directors of the Company have approved the unaudited financial results for the quarter ended on 30th September, 2017 during their respective meetings held on 5th December, 2017.

Indian Accounting Standards (Ind-AS), is applicable to the Company from 1st April, 2017.


The Unaudited Financial Results for the quarter and half year ended on 30th September, 2017 is enclosed, in the format specified under Regulation 33 and 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, duly signed by the authorized director.

Also enclosed is the limited audit review report presented by the Auditors of the Company, on the Unaudited Financial Results for the quarter ended on 30th September, 2017.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Ltd.,



(ASHISH SHAH)
Company Secretary.

Encl.: As Stated Above.

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended on 30/09/2017

| (Rs. In Lacs except EPS) | | | | | | | |
|--------------------------|---|----------------|----------------|----------------|----------------|----------------|---------------------|
| Sr. No. | Particulars | Quarter Ended | | | Year to Date | | Previous Year Ended |
| | | 30/09/2017 | 30/06/2017 | 30/09/2016 | 30/09/2017 | 30/09/2016 | 31/03/17 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1 | Revenue from Operations | 3674.76 | 1699.40 | 2869.44 | 5374.16 | 5099.88 | 10330.59 |
| 2 | Other Income | 94.26 | 111.10 | 62.86 | 205.36 | 136.02 | 295.52 |
| 3 | Total income | 3769.02 | 1810.50 | 2932.30 | 5579.52 | 5235.90 | 10626.11 |
| 4 | Expenses | | | | | | |
| | (a) Cost of Materials Consumed | 202.66 | 189.46 | 157.27 | 392.12 | 320.38 | 804.25 |
| | (b) Purchase of Stock-in-trade | 368.25 | 317.32 | 703.43 | 685.57 | 1083.71 | 2447.12 |
| | (c) Changes in inventories of Finished Goods, Stock-in-trade and WIP | 417.55 | -35.25 | 20.06 | 382.30 | 199.27 | -195.45 |
| | (d) Employee benefit expenses | 704.28 | 644.60 | 558.84 | 1348.88 | 1175.45 | 2425.69 |
| | (e) Finance Costs | 8.65 | 8.82 | 10.78 | 17.47 | 19.82 | 40.99 |
| | (f) Depreciation and Amortisation Expense | 38.09 | 36.09 | 44.65 | 74.18 | 88.76 | 178.71 |
| | (g) other expenses | 742.28 | 940.73 | 737.10 | 1683.01 | 1353.54 | 2876.91 |
| | Total Expenses | 2481.76 | 2101.77 | 2232.13 | 4583.53 | 4240.93 | 8578.22 |
| 5 | Profit before exceptional items & Tax | 1287.26 | -291.27 | 700.17 | 995.99 | 994.97 | 2047.89 |
| 6 | Exceptional Items | | | 0.00 | | 0.00 | 0.00 |
| 7 | Profit before tax | 1287.26 | -291.27 | 700.17 | 995.99 | 994.97 | 2047.89 |
| 8 | Tax Expense | | | | | | |
| | (i) Current Tax | 300.00 | 0.00 | 202.52 | 300.00 | 302.52 | 710.00 |
| | (ii) Income Tax for previous years | 0.00 | 0.00 | -2.89 | 0.00 | -2.89 | 0.00 |
| | (ii) Deferred Tax | -10.04 | -3.33 | -5.51 | -13.37 | -5.45 | -12.87 |
| 9 | Profit after tax for the period | 997.30 | -287.94 | 506.05 | 709.36 | 700.79 | 1350.76 |
| 10 | Other Comprehensive Income | | | | | | |
| | Items that will not be reclassified to profit or loss | | | | | | |
| | (i) | 20.71 | 0.00 | 14.48 | 20.71 | 14.48 | 21.10 |
| | (ii) Income Tax relating to Items that will not be reclassified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 11 | period | 1018.01 | -287.94 | 520.53 | 730.07 | 715.27 | 1371.86 |
| 12 | Rs.) | 21.90 | -6.19 | 11.20 | 15.70 | 15.38 | 29.51 |

Notes:

- The Company has adopted Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act 2013 read with the relevant rules issued thereunder, from April 01, 2017. The Company has adopted all required standards under the IND AS and adoption were carried out in accordance with IND AS 101, first time adoption of IND AS. These unaudited financial result including figures for the quarter and half year ended September 30, 2016, have been prepared in accordance with the recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India.
- The financial results and other financial information for the quarter and half year ended September 30, 2017 have not been audited by the Statutory Auditors. However, the management has exercised necessary due diligence to ensure that the unaudited financial results provide a true and fair view of the Company's affairs.
- The figures of the previous year/period have been regrouped/recast to render them comparable with figures of the current period.

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

Handwritten signature and initials

Handwritten signature

4 Reconciliation of net profit for the quarter ended 30th September 2016, half year ended 30 September 2016, and year ended March 2017 as stated under previous GAAP and IND AS is as under


| Particulars | Profit Reconciliation for the quarter ended | Profit Reconciliation for the Half Year ended | Profit Reconciliation for the year ended 31/03/2017 |
|---|---|---|---|
| Net Profit for the quarter as per Previous GAAP | 503.00 | 697.95 | 1346.45 |
| ADD/(LESS) : Adjustments of difference between figures as per GAAP and IND AS | | | |
| Deferment of Revenue Recognition | 0.47 | 0.95 | 1.9 |
| Restatement of Loss on Sale of Investment to OCI | 0 | 0 | 4.42 |
| Impact of Deferred Tax | 0.57 | 0.03 | 0.05 |
| Discounting of Rent Deposit | -0.87 | -1.03 | -2.06 |
| Income Tax of Previous Years | 2.89 | 2.89 | 0 |
| Net Profit for the quarter as per IND AS | 506.06 | 700.79 | 1350.76 |

5 Reconciliation of equity for the half year ended 30 September 2016, and year ended March 2017 as stated under previous GAAP and IND AS is as under

| Particulars | Equity Reconciliation as on | Equity Reconciliation as on |
|---|-----------------------------|-----------------------------|
| Total Equity as per previous GAAP | 4719.71 | 5365.32 |
| ADD/(LESS) : Adjustments of difference between figures as per GAAP and IND AS | 0 | 0 |
| Adjustment due to valuation of Investment at market value through OCI | 67.42 | 74.04 |
| Deferment of Revenue Recognition | 0.95 | 1.9 |
| Restatement of Loss on Sale of Investment to OCI | 0 | 4.42 |
| Impact of Deferred Tax | 0.03 | 0.05 |
| Discounting of Rent Deposit | -1.03 | -2.06 |
| Net Profit for the quarter as per IND AS | 4787.08 | 5443.67 |

6 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.

By order of the Board
For Jenburkt Pharmaceuticals Ltd.


(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

Place : Mumbai
Date : 05/12/2017

| Standalone Statement of Assets and Liabilities | | | | (Rs.in Lacs) | |
|--|--|------|---------------------|---------------------|--|
| Sr. No. | Particulars | Note | AS AT 30/09/2017 | AS AT 31/03/2017 | |
| | | | (Unaudited) | (Audited) | |
| | ASSETS | | | | |
| (1) | Non Current Assets | | | | |
| (a) | Property, Plants & Equipments | | 990.34 | 1049.81 | |
| (b) | Capital work-in-progress | | | | |
| (c) | Investment Property | | | | |
| (d) | Goodwill | | | | |
| (e) | Other Intangible assets | | 14.19 | 12.83 | |
| (f) | Intangible assets under development | | | | |
| (g) | Biological Assets other than bearer plants | | | | |
| (h) | Financial Assets | | | | |
| | (i) Investments | | 215.47 | 193.70 | |
| | (ii) Trade receivables | | | | |
| | (iii) Loans | | | | |
| | (iv) Others | | | | |
| | (i) Deferred tax assets (net) | | | | |
| | (j) Other non-current assets | | | | |
| (2) | Current assets | | | | |
| (a) | Inventories | | 685.10 | 1074.57 | |
| (b) | Financial Assets | | | | |
| | (i) Investments | | | | |
| | (ii) Trade receivables | | 1102.92 | 907.18 | |
| | (iii) Cash and cash equivalents | | 4097.10 | 4208.40 | |
| | (iv) Bank balance other than (iii) | | | | |
| | (v) Loans | | 67.54 | 64.47 | |
| | (vi) Others (Inventories) | | 403.84 | 129.42 | |
| (c) | Current tax Assets (Net) | | | | |
| (d) | Other current assets | | | | |
| | Total Assets | | 7576.50 | 7640.38 | |
| | EQUITY AND LIABILITIES | | | | |
| | Equity | | | | |
| (a) | Equity Share capital | | 464.93 | 464.93 | |
| (b) | Other Equity - Reserves & Surplus | | 5255.57 | 4978.75 | |
| | LIABILITIES | | | | |
| (1) | Non current liabilities | | | | |
| (a) | Financial Liabilities | | | | |
| | (i) Borrowings | | 23.87 | 24.13 | |
| | (ii) Trade payables | | | | |
| | (iii) Other financial liabilities | | | | |
| (b) | Provisions | | 0.00 | 37.28 | |
| (c) | Deferred tax liabilities (Net) | | 36.90 | 50.27 | |
| (d) | Other non-current liabilities | | 286.79 | 292.74 | |
| (2) | Current Liabilities | | | | |
| (a) | Financial Liabilities | | | | |
| | (i) Borrowings | | 202.53 | 613.36 | |
| | (ii) Trade payables | | 498.28 | 601.62 | |
| | (iii) Other financial liabilities | | | | |
| (b) | Other current liabilities | | 504.73 | 544.56 | |
| (c) | Provisions | | 302.90 | 32.74 | |
| (d) | Current tax liabilities (Net) | | | | |
| | Total Equity and Liabilities | | 7576.50 | 7640.38 | |



D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI –
400034. TEL: 23513758 / 23520330, 9322508373

Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in

Review Report to
The Board of Directors

Jenburkt Pharmaceuticals Ltd.

We have reviewed the accompanying statement of unaudited financial results of Jenburkt Pharmaceuticals Ltd. for the quarter ended 30th September 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D R Mehta & Associates
Chartered Accountants
(FRN. 106207W)



Signature
Ashok Mehta
Partner
(M. No.:101746)



Place: Mumbai
Date 5th December, 2017

ASHOK D. MEHTA
M. NO. 101746

Certificate No. : JPL006